| P2093 | author name string | Chao Ding | |
| | Xian-Tao Song | |
| | Kefeng Li | |
| | Song Cui | |
| | Shu-Zheng Lv | |
| | Li-Jun Meng | |
| P2860 | cites work | Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta | Q24336809 |
| | Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells | Q24337230 |
| | In-stent stenosis: pathology and implications for the development of drug eluting stents | Q24674571 |
| | A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization | Q28202763 |
| | One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial | Q28256012 |
| | Coronary-artery stents | Q28295059 |
| | A novel stent coated with antibodies to endoglin inhibits neointimal formation of porcine coronary arteries | Q33634727 |
| | Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors | Q33887795 |
| | CD105 (endoglin)-negative murine mesenchymal stromal cells define a new multipotent subpopulation with distinct differentiation and immunomodulatory capacities | Q35017103 |
| | Endoglin modulates cellular responses to TGF-beta 1. | Q36236945 |
| | Novel biochemical pathways of endoglin in vascular cell physiology. | Q36381160 |
| | Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury | Q36491946 |
| | Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in ApoE-deficient mice. | Q50488486 |
| | Endoglin has a crucial role in blood cell-mediated vascular repair. | Q52002581 |
| | Different serial changes in the neointimal condition of sirolimus-eluting stents and paclitaxel-eluting stents: an optical coherence tomographic study. | Q53604588 |
| | Endothelial progenitor cell capture stents: will this technology find its niche in contemporary practice? | Q54234614 |
| | Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model | Q67733219 |
| | CD34- blood-derived human endothelial cell progenitors | Q74236979 |
| | The Genous™ endothelial progenitor cell capture stent accelerates stent re-endothelialization but does not affect intimal hyperplasia in porcine coronary arteries | Q84745281 |
| | Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure | Q36640570 |
| | FK506 and rapamycin: novel pharmacological probes of the immune response | Q36654786 |
| | Endoglin regulates the activation and quiescence of endothelium by participating in canonical and non-canonical TGF-β signaling pathways | Q36815716 |
| | Clinical use of sirolimus-eluting stents | Q37031580 |
| | Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model | Q37221177 |
| | Endothelial progenitor cell (EPC) capture to aid vascular repair following coronary stenting: a new frontier in stent technology? | Q37388505 |
| | Late stent thrombosis, endothelialisation and drug-eluting stents | Q37472938 |
| | Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours | Q37610628 |
| | Anti-CD133 antibody immobilized on the surface of stents enhances endothelialization. | Q37664434 |
| | Advantages and disadvantages of biodegradable platforms in drug eluting stents | Q37866105 |
| | Transforming Growth Factor-β and Endoglin Signaling Orchestrate Wound Healing | Q37967810 |
| | Efficacy and safety of sirolimus-eluting stents versus bare-metal stents in coronary artery disease patients with diabetes: a meta-analysis | Q38161765 |
| | Paclitaxel-eluting stents for the treatment of femoropopliteal arterial stenoses: focus on the Zilver PTX drug-eluting peripheral stent | Q38270706 |
| | Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex | Q40177208 |
| | Delayed re-endothelialization with rapamycin-coated stents is rescued by the addition of a glycogen synthase kinase-3beta inhibitor | Q43157373 |
| | Smooth muscle progenitor cells in human blood | Q44123747 |
| | The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts | Q44905265 |
| | Late stent thrombosis after drug-eluting stent implantation for acute myocardial infarction: a new red flag is raised | Q47356923 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2249-2256 | |
| P577 | publication date | 2015-04-17 | |
| P1433 | published in | Drug Design, Development and Therapy | Q2566724 |
| P1476 | title | Comparison of reendothelialization and neointimal formation with stents coated with antibodies against endoglin and CD34 in a porcine model | |
| P478 | volume | 9 | |